Trial Profile
A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- Sponsors TARIS Biomedical
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 22 Aug 2019 Planned End Date changed from 1 Apr 2018 to 1 Oct 2019.
- 26 Jun 2019 Results (positive safety, tolerability and preliminary efficacy data from the full patient cohort (n=20)) presented in a TARIS Biomedical media release.